Healthcare [ 13/13 ] | Medical Devices [ 113/164 ]
NYSE MKT | Common Stock
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.
The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.
Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 Increased by +100.00% | -0.04 Increased by +100.00% |
| Nov 14, 23 | -0.04 Decreased by -33.33% | -0.04 |
| Aug 11, 23 | -0.04 Decreased by -300.00% | -0.03 Decreased by -33.33% |
| May 15, 23 | -0.01 Increased by 0.00% | -0.01 |
| Feb 16, 23 | -0.02 Decreased by -100.00% | -0.01 Decreased by -100.00% |
| Nov 14, 22 | -0.03 Decreased by -50.00% | -0.01 Decreased by -200.00% |
| Sep 28, 22 | -0.01 Increased by 0.00% | -0.01 |
| May 10, 22 | -0.01 Increased by 0.00% | -0.01 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.91 M Decreased by -34.40% | -10.36 M Decreased by -758.00% | Decreased by -542.48% Decreased by -1.21 K% |
| Jun 30, 23 | 1.50 M Decreased by -46.73% | -11.11 M Decreased by -592.39% | Decreased by -740.40% Decreased by -1.20 K% |
| Mar 31, 23 | 1.83 M Decreased by -28.63% | -371.00 K Increased by +83.46% | Decreased by -20.27% Increased by +76.83% |
| Dec 31, 22 | 1.83 M Decreased by -32.29% | -2.20 M Decreased by -107.26% | Decreased by -119.84% Decreased by -206.09% |
| Sep 30, 22 | 2.91 M Increased by +11.92% | -1.21 M Decreased by -62.01% | Decreased by -41.48% Decreased by -44.75% |
| Jun 30, 22 | 2.82 M Increased by +19.37% | -1.60 M Decreased by -84.79% | Decreased by -56.96% Decreased by -54.80% |
| Mar 31, 22 | 2.56 M Increased by +7.55% | -2.24 M Decreased by -214.59% | Decreased by -87.48% Decreased by -192.50% |
| Dec 31, 21 | 2.71 M Increased by +18.91% | -1.06 M Increased by +10.69% | Decreased by -39.15% Increased by +24.89% |